Paper Details

  1. Home
  2. Paper Details

Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.

Author: AabakkenLars, Castro TejeraValeria, FellströmBengt, HauskenTrygve, HovdeØistein, HreinssonJohann P, LindbergGreger, SimrénMagnus, TörnblomHans, VengePer, ÖhmanLena

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Mesalazine was ineffective in reducing irritable bowel syndrome (IBS) symptoms in a randomized, double-blind, placebo-controlled trial. Rectal measures of immune activity by mucosal patch technology could not predict response to mesalazine.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Low-grade immune activation in the gut is a potential treatment target in irritable bowel syndrome (IBS). AIMS: To determine improvement in IBS symptoms after mesalazine treatment, and the utility of measures of immune activity in the rectal mucosa METHODS: This was a randomised, double...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543538/

データ提供：米国国立医学図書館（NLM）

Mesalazine: A New Hope for Irritable Bowel Syndrome?

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that can significantly impact quality of life. This randomized controlled trial investigated the effectiveness of mesalazine, an anti-inflammatory drug, in treating IBS. The study aimed to determine if mesalazine could improve IBS symptoms and modulate immune activity in the rectal mucosa. The results of the trial, combined with a meta-analysis of previous studies, revealed that mesalazine was not effective in reducing IBS symptoms. Despite the lack of significant improvement in overall IBS symptoms, the study showed some potential for mesalazine to alleviate bloating.

Mesalazine: A Mixed Bag for IBS Treatment

The findings of this study suggest that mesalazine is not a viable treatment option for IBS. The lack of significant improvement in overall IBS symptoms, despite some potential benefits for bloating, indicates that mesalazine may not be effective in addressing the diverse range of symptoms associated with IBS.

Navigating the Complexities of IBS: Seeking Effective Solutions

This research highlights the need for further investigation into effective treatments for IBS. The lack of success with mesalazine underscores the complexity of IBS and the need for a multifaceted approach to treatment. It also emphasizes the importance of understanding the individual variations in IBS and tailoring treatment strategies to address specific symptoms.

Dr.Camel's Conclusion

This study provides valuable insights into the potential and limitations of mesalazine for IBS treatment. While mesalazine showed some potential for reducing bloating, it did not significantly improve overall IBS symptoms. This research underscores the need for continued exploration of effective treatment options for IBS, focusing on a personalized approach to address the diverse range of symptoms and individual patient needs.

Date :
  1. Date Completed 2022-08-24
  2. Date Revised 2023-01-29
Further Info :

Pubmed ID

35942522

DOI: Digital Object Identifier

PMC9543538

Related Literature

Article Analysis
・Effects of mesalamine rectal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.